摘要
目的探讨并分析不同剂量阿托伐他汀联合二丁酰环磷酰苷钙对冠心病合并慢性心衰患者心功能及NT—proBNP的影响。方法本研究于某医院内部选取了2017年5月-2018年5月收治的74例冠心病合并慢性心衰患者作为研究对象,采用随机数字表法,将其分为低剂量组和高剂量组,每组各37例。其中,低剂量组给予10mg阿托伐他汀进行治疗,高剂量组给予40mg阿托伐他汀,并联合二丁酰环磷酰苷钙进行治疗,比较两组患者的治疗效果、心功能指标[包括左心室射血分数(LVEF)、二尖瓣舒张晚期/早期的最大血流速度(E/A)、左室短轴缩短率(FS)]以及N末端脑利钠肽前体(NT—proBNP)水平。结果低剂量组患者的治疗有效率为72.97%,高剂量组患者的治疗有效率为94.59%,低剂量组的治疗效果显著低于高剂量组,差异有统计学意义(P <0.05);低剂量组患者心功能的各项指标均低于高剂量组,差异有统计学意义(P <0.05);低剂量组患者的NT—proBNP水平为(387.51±45.21)ng/ml,高剂量组患者的NT—proBNP水平为(321.56±46.36)ng/ml,低剂量组高于高剂量组,差异有统计学意义(P <0.05)。结论在治疗冠心病合并慢性心衰患者的过程中,采用高剂量的阿托伐他汀联合二丁酰环磷酰苷钙,具有更好的治疗效果,且能够有效改善患者的心功能指标,并能够显著降低患者的NT—proBNP水平,因而具有较好的临床应用价值。
Objective To investigate and analyze the effects of different doses of atorvastatin combined with dibutyrylcyclophosphoglycoside calcium on cardiac function and NT-proBNP in patients with coronary heart disease complicated with chronic heart failure. Methods In this study, 74 patients with coronary heart disease complicated with chronic heart failure who were treated from May 2017 to May 2018 were selected as study objects. They were divided into low-dose group and high-dose group by random number table method, with 37 cases in each group. Low-dose group was given 10 mg atorvastatin for treatment, high-dose group was given40 mg atorvastatin and combined with dibutyrylcyclophosphoglycoside calcium, the treatment effect of two groups, heart function indicators including the left ventricle Ejection fraction(LVEF), late mitral/diastolic maximum velocity(E/A), short left ventricular shortening(FS)and N-terminal brain natriuretic peptide(NT-proBNP)levels were compared. Results The effective rate was 72.97% in the low-dose group and 94.59% in the high-dose group. The treatment effect was significantly lower in the low-dose group than in the high-dose group(P < 0.05). The indexes of cardiac function in low-dose group were lower than those in high-dose group(P < 0.05). The level of NT-proBNP in low-dose group were(387.51±45.21)ng/ml, while that in high dose group was(321.56±46.36)ng/ml, which was lower than that in low-dose group. The difference was statistically significant(P < 0.05). Conclusion In the treatment of patients with coronary heart disease complicated with chronic heart failure, the use of high-dose atorvastatin combined with calcium dibutyrylcyclophosphoglycoside has a better therapeutic effect, and it can effectively improve the patient’s heart function indicators, and can Significantly reduce the patient’s NT-proBNP levels, so it has a good clinical application value.
作者
台来提.吐尔洪
Tai Lai ti·tu er hong(Department of the second division of Internal Medicine,West Branch,the People's Hospital of Hetian area,Xinjiang,Hetian,848000,China)
出处
《新疆医学》
2018年第10期1086-1088,共3页
Xinjiang Medical Journal
